Products
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
BAYER AG
π©πͺ
Germany
Country
π©πͺ
Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Phase 2
Completed
Conditions
Colorectal Neoplasms
Interventions
Drug: Regorafenib (Stivarga, BAY73-4506)
Subscribe
First Posted Date
2015-06-08
Last Posted Date
2018-11-07
Lead Sponsor
Bayer
Target Recruit Count
59
Registration Number
NCT02465502
Subscribe
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
Phase 1
Completed
Conditions
Medical Oncology
Interventions
Drug: Roniciclib (BAY 1000394)
Drug: Itraconazole (Sporanox)
Subscribe
First Posted Date
2015-05-29
Last Posted Date
2016-05-23
Lead Sponsor
Bayer
Target Recruit Count
14
Registration Number
NCT02457351
Subscribe
Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan
Phase 1
Completed
Conditions
Clinical Trial, Phase I
Interventions
Drug: Vilaprisan (BAY1002670)
Drug: [14C] Vilaprisan
Other: Itraconazole(ITZ)
Subscribe
First Posted Date
2015-05-28
Last Posted Date
2016-03-02
Lead Sponsor
Bayer
Target Recruit Count
14
Registration Number
NCT02456129
Subscribe
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase 2
Terminated
Conditions
Lymphoma, Mantle-Cell
Interventions
Drug: Copanlisib (BAY80-6946)
Subscribe
First Posted Date
2015-05-27
Last Posted Date
2017-10-02
Lead Sponsor
Bayer
Target Recruit Count
4
Registration Number
NCT02455297
Subscribe
A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction
Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: BAY1142524
Drug: Placebo
Subscribe
First Posted Date
2015-05-22
Last Posted Date
2017-11-07
Lead Sponsor
Bayer
Target Recruit Count
49
Registration Number
NCT02452515
Subscribe
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Completed
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
Subscribe
First Posted Date
2015-05-21
Last Posted Date
2021-11-02
Lead Sponsor
Bayer
Target Recruit Count
86
Registration Number
NCT02450812
Locations
π©πͺ
Many Locations, Multiple Locations, Germany
Subscribe
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Phase 1
Completed
Conditions
Neoplasms
Bone Diseases
Interventions
Drug: Radium Ra 223 dichloride (Xofigo, BAY88-8223)
Drug: paclitaxel
Subscribe
First Posted Date
2015-05-13
Last Posted Date
2016-11-30
Lead Sponsor
Bayer
Target Recruit Count
15
Registration Number
NCT02442063
Subscribe
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
Phase 1
Terminated
Conditions
Medical Oncology
Interventions
Drug: BAY1143269 tablet
Subscribe
First Posted Date
2015-05-08
Last Posted Date
2018-03-07
Lead Sponsor
Bayer
Target Recruit Count
15
Registration Number
NCT02439346
Subscribe
Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women
Phase 1
Completed
Conditions
Endometriosis
Interventions
Drug: BAY1128688
Drug: Placebo
Subscribe
First Posted Date
2015-05-05
Last Posted Date
2016-05-19
Lead Sponsor
Bayer
Target Recruit Count
51
Registration Number
NCT02434640
Subscribe
Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
Completed
Conditions
Hypertension, Pulmonary
Interventions
Drug: Riociguat (ADEMPAS, BAY63-2521)
Subscribe
First Posted Date
2015-04-29
Last Posted Date
2024-01-29
Lead Sponsor
Bayer
Target Recruit Count
882
Registration Number
NCT02428985
Locations
π―π΅
Many Locations, Multiple Locations, Japan
Subscribe
Prev
1
70
71
72
73
74
163
Next
Β© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy